| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
60,481 |
45,404 |
$1.59M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
23,354 |
18,311 |
$415K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
24,359 |
18,729 |
$268K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
15,260 |
12,288 |
$258K |
| 90791 |
Psychiatric diagnostic evaluation |
6,715 |
5,176 |
$200K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,042 |
795 |
$52K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
914 |
832 |
$26K |
| 64483 |
|
151 |
118 |
$10K |
| 64493 |
|
149 |
79 |
$7K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
205 |
175 |
$7K |
| 64494 |
|
105 |
53 |
$3K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
481 |
352 |
$3K |
| 20610 |
|
73 |
52 |
$2K |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
387 |
282 |
$2K |
| 64635 |
|
14 |
12 |
$2K |
| 64636 |
|
14 |
12 |
$650.93 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
628 |
484 |
$308.23 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
443 |
325 |
$250.01 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
18 |
14 |
$43.58 |
| 99441 |
|
17 |
13 |
$22.13 |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
332 |
263 |
$9.06 |
| G8428 |
Current list of medications not documented as obtained, updated, or reviewed by the eligible clinician, reason not given |
221 |
213 |
$0.00 |
| G8430 |
Documentation of a medical reason(s) for not documenting, updating, or reviewing the patient's current medications list (e.g., patient is in an acute health crisis where time is of the essence and delay of treatment would jeopardize the patient's health status) |
29 |
21 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
11,405 |
8,148 |
$0.00 |
| G8730 |
Pain assessment documented as positive using a standardized tool and a follow-up plan is documented |
3,225 |
2,646 |
$0.00 |